3 days popular7 days popular1 month popular3 months popular

Research finds surgical marker helps cut cost of breast cancer treatment

Breast cancer research conducted by two Fayetteville medical groups highlights their success in pioneering use of an absorbable, three-dimensional marker used during treatment for breast cancer. Their cost analysis, to be presented at an international breast cancer conference this week, showed that by helping to shorten the course of radiation treatments, the surgical marker contributed [...]

Survivors of childhood cancer have high-risk of recurrent stroke

Findings have clinical implications on how we treat and follow survivors Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood cancer have a high risk of suffering a stroke at a surprisingly young age. A new study from the UC San Francisco Pediatric Brain Center shows that childhood [...]

Proposed 2016 Medicare physician cuts threaten access to community-based radiation therapy

The American Society for Radiation Oncology (ASTRO) is concerned about proposed additional payment cuts to radiation therapy detailed in the Centers for Medicare and Medicaid Services’ (CMS) proposed Medicare Physician Fee Schedule (MPFS), released July 8, 2015, which will take effect on January 1, 2016. Freestanding centers estimate that the combined impact of the Medicare [...]

Researchers develop first genetic test to predict tumor sensitivity to radiation therapy

Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient’s response to therapy. Moffitt Cancer Center researchers have contributed to these advances by developing the first test that analyzes the sensitivity of [...]

Study supports IDH gene as prognostic marker in anaplastic astrocytoma

New findings suggest that a gene called IDH1 might be prognostic marker for a rare form of brain cancer. Patients in this study who had a mutated IDH gene lived an average of 7.9 years after diagnosis versus 2.8 years for patients with unaltered IDH. The IDH study was done as part of the phase [...]